pharma · Metastatic Prostate Cancer · Prostate Cancer · TLX
Telix Innovations
Telix Innovations clinical programs — 11 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Rue de Hermée 255, Herstal, Région wallonne 4040, BE
- Founded
- 2015
- Employees
- 14
- Programs
- 27
- Drugs
- 11
- Patents
- 3
Telix Innovations projects
11 ClinicalTrials.gov programs sponsored by Telix Innovations.
Telix Innovations has 11 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
131I-IPA
Telix Innovations
Neoplastic Disease
1 trial -
153Sm-DOTMP
Telix Innovations
Bone Pain
1 trial -
177Lu-DOTA-TLX591
Telix Innovations
Metastatic Prostate Cancer
1 trial -
177Lu-TLX250 and Peposertib
Telix Innovations
Solid Tumor, Adult
1 trial -
64Cu-DOTA-TLX592
Telix Innovations
Metastatic Prostate Cancer
1 trial -
68-Ga PSMA11
Telix Innovations
Prostate Adenocarcinoma
1 trial -
89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)
Telix Innovations
Soft Tissue Sarcoma
1 trial -
89Zr-Girentuximab
Telix Innovations
Clear Cell Renal Carcinoma
1 trial -
89Zr-Girentuximab
Telix Innovations
Urothelial Carcinoma
1 trial -
89Zr-girentuximab
Telix Innovations
Carcinoma, Renal Cell
1 trial -
illuccix 68Ga-PSMA-11 Total Body PET-CT
Telix Innovations
Metastatic Castration-resistant Prostate Cancer
1 trial
Frequently asked questions
How many clinical projects does Telix Innovations have?
11 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.